Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data.
about
Trastuzumab-containing regimens for metastatic breast cancerFluid biopsy for solid tumors: a patient's companion for lifelong characterization of their diseaseEfficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-AnalysisStrategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patientHER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.Use of genomic signatures in therapeutics development in oncology and other diseases.Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance.Epidermal growth factor receptor inhibition and non-small cell lung cancer.Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease.Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer.Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.Updates on the Molecular Pathology of Selected Ocular and Ocular Adnexal Tumors: Potential Targets for Future Therapy.Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.Twenty-years experience with de novo metastatic breast cancer.Intrinsic cancer subtypes-next steps into personalized medicine
P2860
Q24194019-7A0FEA17-3585-4A85-A109-C8E47E0A6B6AQ24623374-3F5D493F-11EB-424C-B08C-B2ABA4199F57Q28547354-83F08B8B-FB06-4E84-AA2B-B4A0143F0F76Q30857631-DBD17C2C-5288-4E0D-92DC-99292E190873Q33236634-9536535C-791A-4C1E-8D8F-6EC833682D8DQ33409083-D3934D66-E56B-4488-9DF0-8DC594D949A2Q33728102-AD7BD6A1-DA84-4367-ADD2-763A921750FDQ33737278-37E8ED97-1AA7-4009-9D0C-06D417097CE7Q34983601-FF8F3DD9-8BCD-40C3-B6C6-FD3402AD5A1BQ36107134-64AC6CAF-FB33-4188-A754-6E567278F340Q36369836-E1693B99-79BD-4C72-92FF-B6ADA04AE246Q36496394-8247DAA2-5DE1-4849-A7DB-CD12E2EF107CQ36504349-00DDCFA9-6FF1-434E-9F8B-EF3A02CADD8EQ36615272-25B3B236-A592-46E9-9470-4E0205F48F35Q36896150-C9B5C9FC-EB35-4416-8668-FEB2147E2622Q36977501-41DF8F99-C0B6-4676-91CB-FA2FCB4780D3Q37827010-F43C8178-8EC7-4751-9F25-DB2CFF6269E0Q38209463-629F7CAF-70A1-4A9A-9355-A25446B5DE05Q38766864-C02F239D-E550-4385-ACBB-4BD1B1CBA4B7Q47161064-2C015077-2B03-424D-811D-CF1EAB5F2B87Q49544395-72094BE5-18A3-4744-9EC9-E04D80228223Q50630417-D7D99D86-557E-48A4-9E70-4D6177FB202BQ51653536-59D1B34F-50C4-4409-9058-6F7D8ACB22ADQ58053534-9AC49CCF-E152-4273-BED7-F1914DBC9288
P2860
Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Trastuzumab combined with chem ...... st cancer: pivotal trial data.
@ast
Trastuzumab combined with chem ...... st cancer: pivotal trial data.
@en
type
label
Trastuzumab combined with chem ...... st cancer: pivotal trial data.
@ast
Trastuzumab combined with chem ...... st cancer: pivotal trial data.
@en
prefLabel
Trastuzumab combined with chem ...... st cancer: pivotal trial data.
@ast
Trastuzumab combined with chem ...... st cancer: pivotal trial data.
@en
P356
P1433
P1476
Trastuzumab combined with chem ...... st cancer: pivotal trial data.
@en
P2093
International Herceptin Study Group
W Eiermann
P304
P356
10.1093/ANNONC/12.SUPPL_1.S57
P478
12 Suppl 1
P577
2001-01-01T00:00:00Z